NL301256I1 - - Google Patents

Info

Publication number
NL301256I1
NL301256I1 NL301256C NL301256C NL301256I1 NL 301256 I1 NL301256 I1 NL 301256I1 NL 301256 C NL301256 C NL 301256C NL 301256 C NL301256 C NL 301256C NL 301256 I1 NL301256 I1 NL 301256I1
Authority
NL
Netherlands
Application number
NL301256C
Other versions
NL301256I2 (nl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NL301256I1 publication Critical patent/NL301256I1/nl
Publication of NL301256I2 publication Critical patent/NL301256I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NL301256C 2007-10-16 2023-12-27 cedazuridine, of een farmaceutisch aanvaardbaar zout daarvan NL301256I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98039707P 2007-10-16 2007-10-16
PCT/US2008/080163 WO2009052287A1 (en) 2007-10-16 2008-10-16 2 ' -flu0r0-2 ' -deoxytetrahydrouridines as cytidine deaminase inhibitors

Publications (2)

Publication Number Publication Date
NL301256I1 true NL301256I1 (nl) 2024-01-03
NL301256I2 NL301256I2 (nl) 2024-01-11

Family

ID=40251685

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301256C NL301256I2 (nl) 2007-10-16 2023-12-27 cedazuridine, of een farmaceutisch aanvaardbaar zout daarvan

Country Status (39)

Country Link
US (4) US8268800B2 (nl)
EP (2) EP2447272B1 (nl)
JP (2) JP5496899B2 (nl)
KR (1) KR101543049B1 (nl)
CN (1) CN101827856B (nl)
AT (1) ATE548374T1 (nl)
BR (1) BRPI0818672B8 (nl)
CA (1) CA2702274C (nl)
CO (1) CO6270330A2 (nl)
CR (1) CR11427A (nl)
CY (3) CY1112781T1 (nl)
DK (1) DK2207786T3 (nl)
EA (1) EA018757B1 (nl)
EC (1) ECSP10010095A (nl)
ES (2) ES2384011T3 (nl)
FI (2) FIC20230040I1 (nl)
FR (2) FR23C1052I1 (nl)
GT (1) GT201000088A (nl)
HK (1) HK1146410A1 (nl)
HR (1) HRP20120419T1 (nl)
HU (2) HUS2300045I1 (nl)
IL (1) IL204732A (nl)
JO (1) JO2778B1 (nl)
ME (1) ME00997B (nl)
MX (1) MX2010004109A (nl)
MY (1) MY147970A (nl)
NI (1) NI201000055A (nl)
NL (1) NL301256I2 (nl)
NO (2) NO2023048I1 (nl)
NZ (1) NZ584229A (nl)
PL (1) PL2207786T3 (nl)
PT (1) PT2207786E (nl)
RS (1) RS52323B (nl)
SA (1) SA08290661B1 (nl)
SI (1) SI2207786T1 (nl)
TW (1) TWI445539B (nl)
UA (1) UA99476C2 (nl)
WO (1) WO2009052287A1 (nl)
ZA (1) ZA201002178B (nl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
EP2299984B1 (en) 2008-05-15 2018-11-28 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US20100055047A1 (en) * 2008-08-26 2010-03-04 Yiyu Zou Methods for treating bronchial premalignancy and lung cancer
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
EP2416781B1 (en) * 2009-04-06 2017-03-08 Otsuka Pharmaceutical Co., Ltd. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
TWI477508B (zh) * 2009-04-06 2015-03-21 Otsuka Pharma Co Ltd 用以治療癌症之組成物及方法
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
JP5730854B2 (ja) * 2009-04-06 2015-06-10 大塚製薬株式会社 デシタビンとシチジンデアミナーゼ阻害剤との組合せ、およびがんの治療におけるその使用
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
HUE026235T2 (en) 2010-03-31 2016-06-28 Gilead Pharmasset Llc Crystalline (S) -isopropyl 2 - (((S) - (((2R, 3R, 4R, 5R) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2H) -IL) - 4-Fluoro-3-hydroxy-4-methyltetrahydrofuran-2-IL) methoxy) (phenoxy) phosphoryl) amino) propanoate
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
TW201242974A (en) 2010-11-30 2012-11-01 Gilead Pharmasset Llc Compounds
PL2709613T5 (pl) 2011-09-16 2020-12-14 Gilead Pharmasset Llc Metody leczenia hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
SG10201706949VA (en) 2013-01-31 2017-09-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
MX2016002185A (es) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.
RU2681939C2 (ru) 2013-10-29 2019-03-14 Оцука Фармасьютикал Ко., Лтд. Путь синтезирования 2'-дезокси-2'2'-дифтортетрагидроуридинов
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
CA2958867A1 (en) 2014-08-22 2016-02-25 Anjan THAKURTA Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
CN109789155A (zh) 2015-12-03 2019-05-21 免疫规划公司 含有地西他滨、5-氮杂胞苷和四氢尿苷的组合物以及其用途
WO2017158396A1 (en) 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
EP3746134A1 (en) 2018-02-02 2020-12-09 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
US11224610B2 (en) * 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
JP7433662B2 (ja) * 2018-10-19 2024-02-20 インターオリゴ・コーポレイション 治療効能を改善した核酸変形体及びそれを含む抗癌用薬学組成物
EP3868774A4 (en) * 2018-10-19 2023-05-10 Interoligo Corporation MODIFIED NUCLEIC ACID WITH IMPROVED TREATMENT EFFICIENCY AND ANTI-CANCER PHARMACEUTICAL COMPOSITION THEREOF
KR20220078619A (ko) * 2019-10-08 2022-06-10 오츠카 세이야쿠 가부시키가이샤 고순도의 2'-데옥시-2',2'-디플루오로테트라히드로우리딘 및 그의 제조 방법
CA3163122A1 (en) * 2020-02-25 2021-09-02 Aram Oganesian Combination decitabine and cedazuridine solid oral dosage forms
BR112023019182A2 (pt) * 2021-03-26 2023-11-28 Cleveland Clinic Found Uso de um inibidor de citidina desaminase na preparação de um medicamento, sistema, kit ou artigo de manufatura e composição
WO2022254457A1 (en) * 2021-05-29 2022-12-08 Msn Laboratories Private Limited, R&D Center An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
WO2023069529A1 (en) 2021-10-19 2023-04-27 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
WO2023076332A1 (en) * 2021-11-01 2023-05-04 St. John's University Injectable liquid pharmaceutical compostion containing gemcitabine and a cytidine deaminase inhibitor
US20230271996A1 (en) * 2021-12-25 2023-08-31 Scinopharm Taiwan, Ltd. Process for preparing cedazuridine
WO2024047394A1 (en) 2022-08-31 2024-03-07 Otsuka Pharmaceutical Co., Ltd. Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017606A (en) * 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
US4210638A (en) * 1978-03-17 1980-07-01 Pcr, Inc. Antiviral composition and method of treating virus diseases
US4275057A (en) 1980-01-28 1981-06-23 The United States Of America As Represented By The Department Of Health, Education And Welfare Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
DE3481172D1 (de) 1983-10-26 1990-03-08 Sheldon B Greer Verfahren und materialien zum empfindlichmachen eines neoplastischen gewebes vor strahlung.
IL77133A (en) * 1984-12-04 1991-01-31 Lilly Co Eli Antineoplastic pharmaceutical compositions containing pentofuranoside derivatives,some new such compounds and their preparation
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5223608A (en) * 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
WO1992018617A1 (en) 1991-04-23 1992-10-29 Oglevee, Ltd. In vitro leaf petiole multiplication of pelargoniums
FR2682112B1 (fr) * 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5821357A (en) * 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5371210A (en) * 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5594124A (en) * 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5426183A (en) * 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5606048A (en) * 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
AU664948B2 (en) * 1993-02-23 1995-12-07 City Of Hope 4-ethoxy 5-fluoro 2'deoxyuridine
WO1994026761A1 (en) * 1993-05-14 1994-11-24 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) * 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
WO1996026743A1 (en) * 1995-03-01 1996-09-06 Human Gene Therapy Research Institute Radiation enhanced gene therapy for treatment of tumors
US6001994A (en) * 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5760208A (en) * 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
EP1156827B1 (en) * 1999-03-01 2006-09-20 Halogenetics, Inc. USE OF COMPOSITIONS COMPRISING CldC AS RADIOSENSITIZERS IN THE TREATMENT OF NEOPLASTIC DISEASES
US6933287B1 (en) * 1999-03-01 2005-08-23 Sheldon B. Greer Dramatic simplification of a method to treat neoplastic disease by radiation
WO2001013789A1 (en) 1999-08-26 2001-03-01 Aortech International Plc Improvements relating to catheter positioning
US6462191B1 (en) * 2000-07-13 2002-10-08 Air Products And Chemicals, Inc. Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
DE60144573D1 (de) * 2000-11-29 2011-06-16 Mitsui Chemicals Inc Verfahren und Zwischenprodukte bei der Synthese von L-Thymidin
ES2236481T3 (es) * 2001-01-16 2005-07-16 Glaxo Group Limited Combinacion farmaceutica que contiene una 4-quinazolinamina y paclitaxel, carboplatino o vinorelbina para el tratamiento de cancer.
EP1387850A2 (en) 2001-05-18 2004-02-11 Rakesh Kumar Antiviral nucleosides
US8207142B2 (en) * 2001-07-31 2012-06-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibitor of DNA methylation
BR0307712A (pt) 2002-02-14 2005-05-24 Pharmasset Ltd Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
JP2006507255A (ja) 2002-09-24 2006-03-02 コローニス ファーマシューティカルズ インコーポレイテッド ウイルス疾患の治療のための１，３，５−トリアジン
AU2003291726A1 (en) 2002-11-04 2004-06-07 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
US8158770B2 (en) * 2004-05-06 2012-04-17 University Of Rochester Content dependent inhibitors of cytidine deaminases and uses thereof
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
CN101076536A (zh) 2004-07-30 2007-11-21 药华医药股份有限公司 β－核苷的立体选择性合成
TW200634022A (en) 2004-12-08 2006-10-01 Sicor Inc Difluoronucleosides and process for preparation thereof
WO2008085611A2 (en) * 2006-11-27 2008-07-17 University Of Miami Designer theraphy of pancreatic tumors
WO2009021551A1 (en) 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
WO2010047698A1 (en) 2008-10-22 2010-04-29 University Of Alabama At Birmingham Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
EP2416781B1 (en) * 2009-04-06 2017-03-08 Otsuka Pharmaceutical Co., Ltd. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
TWI477508B (zh) * 2009-04-06 2015-03-21 Otsuka Pharma Co Ltd 用以治療癌症之組成物及方法
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
JP5730854B2 (ja) * 2009-04-06 2015-06-10 大塚製薬株式会社 デシタビンとシチジンデアミナーゼ阻害剤との組合せ、およびがんの治療におけるその使用

Also Published As

Publication number Publication date
KR20100091978A (ko) 2010-08-19
NZ584229A (en) 2012-06-29
BRPI0818672B1 (pt) 2020-10-20
AU2008312435A1 (en) 2009-04-23
JO2778B1 (en) 2014-03-15
US8951987B2 (en) 2015-02-10
KR101543049B1 (ko) 2015-08-07
US9567363B2 (en) 2017-02-14
PT2207786E (pt) 2012-05-28
AU2008312435A8 (en) 2014-07-24
NI201000055A (es) 2010-08-13
UA99476C2 (en) 2012-08-27
PL2207786T3 (pl) 2012-09-28
ES2616566T3 (es) 2017-06-13
ES2384011T3 (es) 2012-06-28
FR23C1051I1 (fr) 2024-01-26
US20150210730A1 (en) 2015-07-30
CN101827856A (zh) 2010-09-08
SA08290661B1 (ar) 2012-06-10
CO6270330A2 (es) 2011-04-20
CA2702274A1 (en) 2009-04-23
US20140186335A1 (en) 2014-07-03
TWI445539B (zh) 2014-07-21
FR23C1052I1 (fr) 2024-01-26
GT201000088A (es) 2012-03-13
HUS2300045I1 (hu) 2024-01-28
AU2008312435B2 (en) 2014-04-17
EP2447272A1 (en) 2012-05-02
US8268800B2 (en) 2012-09-18
EA018757B1 (ru) 2013-10-30
NO2023048I1 (en) 2023-12-21
WO2009052287A1 (en) 2009-04-23
CY1112781T1 (el) 2016-02-10
JP5496899B2 (ja) 2014-05-21
EP2447272B1 (en) 2017-02-01
NL301256I2 (nl) 2024-01-11
ME00997B (me) 2012-10-20
BRPI0818672A2 (pt) 2015-04-14
MY147970A (en) 2013-02-28
FIC20230039I1 (fi) 2023-12-22
CY2023028I1 (el) 2024-02-16
TW200924786A (en) 2009-06-16
CN101827856B (zh) 2013-02-06
RS52323B (en) 2012-12-31
DK2207786T3 (da) 2012-06-18
ATE548374T1 (de) 2012-03-15
BRPI0818672B8 (pt) 2021-05-25
HK1146410A1 (en) 2011-06-03
US8618075B2 (en) 2013-12-31
ZA201002178B (en) 2011-05-25
EP2207786A1 (en) 2010-07-21
JP5859588B2 (ja) 2016-02-10
JP2014177455A (ja) 2014-09-25
CA2702274C (en) 2015-12-29
ECSP10010095A (es) 2010-07-30
IL204732A (en) 2013-07-31
FIC20230040I1 (fi) 2023-12-22
CR11427A (es) 2010-08-16
NO2023047I1 (no) 2023-12-21
CY2023029I1 (el) 2024-02-16
US20120289475A1 (en) 2012-11-15
SI2207786T1 (sl) 2012-10-30
HUS2300044I1 (hu) 2024-01-28
MX2010004109A (es) 2010-08-10
EA201000642A1 (ru) 2010-10-29
EP2207786B1 (en) 2012-03-07
HRP20120419T1 (hr) 2012-07-31
IL204732A0 (en) 2010-11-30
US20090137521A1 (en) 2009-05-28
JP2011500713A (ja) 2011-01-06

Similar Documents

Publication Publication Date Title
CN300729247S (zh) 手锯(bt306a)
CN300730950S (zh) 甲虫按摩器(ym-006)
CN300730800S (zh) 蜡烛(223)
CN300928447S (zh) 通讯头戴式送受话器
CN300726094S (zh) 餐具笼(花瓶形2003)
CN300890770S (zh) 酒瓶(蓝日进斗金瓶)
CN300726269S (zh) 墙纸(29a)
CN300863862S (zh) 枕套(d-18)
CN300857380S (zh) 沙发(r179组合)
CN300730676S (zh) 烛台(85)
CN300730596S (zh) 瓷砖(玉韵石-6la265)
CN300726619S (zh) 茶壶(01)
CN300731275S (zh) 面料(艺术染整2007-06)
CN300731345S (zh) 镶嵌玻璃(185)
CN300731439S (zh) 床(h-1689)
CN300730498S (zh) 牙刷挂具(三)
CN300855771S (zh) 漏电断路器(2极)
CN300730272S (zh) 橡皮(k-0715)
CN300726703S (zh) 胡椒瓶(不锈钢)
CN300730171S (zh) 太阳能泵站
CN300822391S (zh) 浴室取暖器(s525b)
CN300730134S (zh) 电路板(电流电压输入端子板)
CN300729906S (zh) 轴输出裂极式同步电机
CN300731536S (zh) 橱(二)
CN300729747S (zh) 工艺画